Novartis Teams Up With Sangamo In Brain Gene Therapy Pact

Autism At The Center of Collaboration

Novartis is the latest big pharma to sign up for access to Sangamo's gene therapy technologies, inking a deal that will focus on neurodevelopment disorders and could be worth in the region of $800m.

Woman_DNA
Tackling brain disorders with gene therapies • Source: Shutterstock

Novartis AG is paying $75m upfront to use Sangamo Therapeutics, Inc.'s zinc finger technology platform and develop genomic medicines for autism, a long-time area of interest for the Swiss major, and other neurodevelopmental disorders.

The three-year collaboration will see Novartis get exclusive rights to Sangamo's zinc finger protein transcription factors (ZFP-TFs) targeted to three...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category